BioSpace News Archive

MedAxiom, the nation’s leading cardiovascular healthcare performance community and top CV-specific consulting firm, has released its sixth annual Cardiovascular Provider Compensation & Production Survey—a highly sought-after resource for healthcare decision-makers.

On October 19, 2018, thousands of people across the country will stand in solidarity with those affected by cancer as part of National Be Bold, Be Bald! Day.

For Eyes, one of the national leaders in optical retail, is helping to promote preventative eye health for World Sight Day, an annual day of awareness that focuses on the global problem of blindness and visual impairment.

Persons wishing to learn their genetic risk for Alzheimer’s disease should first consider consulting with their doctor and a genetic counselor, according to a commentary authored by AFA’s Medical, Scientific & Memory Screening Advisory Board, among other recommendations aimed at physician-scientists, policymakers, and the commercial genetic testing industry.

Optimum Nutrition (ON) will introduce a new lightly carbonated “anytime energy” beverage, ESSENTIAL AMIN.O. ENERGY PLUS ELECTROLYTES™ to the convenience channel at the NACS Show 2018 in Las Vegas, Nevada.

Concordia International Corp. (“Concordia” or the “Company”) (TSX: CXR), today issued a notice of meeting (the “Meeting”) of shareholders to consider and approve a name change (the “Name Change”) of the Company.

Thousands of FED UP! supporters, a grassroots coalition of organizations and families directly impacted by the nation’s opioid addiction epidemic, are descending on the capital Columbus Day weekend to raise awareness of the epidemic’s devastating impact and to demand urgent action from the federal government.

The U.S. Food and Drug Administration today approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved use of the vaccine to include women and men aged 27 through 45 years. Gardasil 9 prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine.

Endologix® Inc. announced today that it has received notice that the U.S. Food and Drug Administration (FDA) has classified a voluntary recall action that Endologix took in July of this year as a Class I recall.

Medical booths at annual conferences such as the American Society of Hematology are a prime opportunity to highlight a pharmaceutical company’s pipeline and products to healthcare professionals.